EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Chimeric Antigen Receptor—Macrophages in Pancreatic Cancer: Promise, Pitfalls, and the Path Ahead

Palloma Porto Almeida, Leandro Martins de Freitas

Frontiers in Bioscience-Elite · 28.05.2026 · 18 (2)

DOI: 10.31083/fbe45762 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Elite, online erschienen am 28.05.2026. Verfasst von Palloma Porto Almeida und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Receptors, Chimeric Antigen, Macrophages, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor–engineered macrophages (CAR-Ms) are emerging as a transformative frontier in immunotherapy and represent a promising strategy for pancreatic cancer. Unlike chimeric antigen receptor T-cell (CAR-T) or chimeric antigen receptor natural killer cell (CAR-NK) cells, which encounter limitations when applied to solid tumors, CAR-Ms combine innate tumor-homing capabilities with engineered antigen specificity to overcome these barriers. Recent studies have demonstrated encouraging antitumor activity in preclinical pancreatic ductal adenocarcinoma (PDAC) models; however, key questions remain regarding the persistence, safety, and scalability of these models. Nonetheless, despite these uncertainties, CAR-Ms may represent a paradigm shift from immune activation focused solely on direct cytotoxicity to one that also integrates immune orchestration and tumor microenvironmental reprogramming.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsReceptors, Chimeric AntigenMacrophagesCarcinoma, Pancreatic DuctalHumansAnimalsTumor MicroenvironmentImmunotherapy

Stichwörter der Autor:innen

cellular therapychimeric antigen receptormacrophagestumor microenvironment

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil.
  • Multidisciplinary Institute of Health, Federal University of Bahia, Vitória da Conquista, BA 45029-094, Brazil.

Zitieren

APA

Almeida, P. P., & de Freitas, L. M. (2026). Chimeric Antigen Receptor—Macrophages in Pancreatic Cancer: Promise, Pitfalls, and the Path Ahead. Frontiers in Bioscience-Elite, 18(2). https://doi.org/10.31083/fbe45762

Vancouver

Almeida PP, de Freitas LM. Chimeric Antigen Receptor—Macrophages in Pancreatic Cancer: Promise, Pitfalls, and the Path Ahead. Frontiers in Bioscience-Elite. 2026;18(2). doi:10.31083/fbe45762

BibTeX
@article{Almeida2026,
  author = {Almeida, Palloma Porto and de Freitas, Leandro Martins},
  title = {Chimeric Antigen Receptor—Macrophages in Pancreatic Cancer: Promise, Pitfalls, and the Path Ahead},
  journal = {Frontiers in Bioscience-Elite},
  year = {2026},
  volume = {18},
  number = {2},
  doi = {10.31083/fbe45762}
}
Kostenlos starten →